Skip to content. Skip to main navigation.

Recombinant DNA - IBC


All projects involving recombinant DNA, regardless of funding, must be reviewed by the UT Arlington Institutional Biosafety Committee (IBC) prior to initiation.

The University of Texas at Arlington complies with the NIH Guidelines for Research Involving Recombinant DNA Molecules, effective June 24, 1994, published in Federal Register July 5, 1994, (59 FR 34496) and all subsequent amendments issued by the NIH Director.  In addition, UT Arlington follows the guidance found in Biosafety in Microbiological and Biomedical Laboratories, CDC/NIH, Fifth Edition, February 2007.


Recombinant DNA molecules are defined as either:  (i) molecules that are constructed outside living cells by joining natural or synthetic DNA segments to DNA molecules that can replicate in a living cell, or (ii) molecules that result from the replication of those described in (i) above.

Synthetic DNA segments which are likely to yield a potentially harmful polynucleotide or polypeptide (e.g., a toxin or a pharmacologically active agent) are considered as equivalent to their natural DNA counterpart. 

Genomic DNA of plants and bacteria that have acquired a transposable element, even if the latter was donated from a recombinant vector no longer present, are not subject to the NIH Guidelines unless the transposon itself contains recombinant DNA.

For assistance or additional information, including meeting times and locations, contact the Office of Regulatory Services: 817-272-3723 or